Announced
Completed
Synopsis
Idera Pharmaceuticals, a pharmaceutical solutions provider, completed the acquisition of Aceragen, a privately-held biotechnology company. Financial terms were not disclosed. “After a thorough evaluation of strategic alternatives, we and our Board of Directors believe this acquisition represents the highest potential value creation opportunity for Idera’s stockholders. We are excited by the potential for Aceragen’s rare disease portfolio to result in meaningful therapeutic options for patients, and I am looking forward to being part of this new stage of Idera’s journey,” Vincent Milano, Idera Chair of the Board.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.